|Bid||17.46 x 300|
|Ask||17.49 x 1900|
|Day's Range||17.22 - 18.01|
|52 Week Range||16.81 - 53.96|
|PE Ratio (TTM)||224.23|
|Dividend & Yield||1.10 (6.43%)|
|1y Target Est||N/A|
Citigroup cut its rating for the struggling generic drug maker to 'neutral'.
A small gain still would have been better than the results Hertz Global Holdings, Inc (NYSE:HTZ), Transocean LTD (NYSE:RIG) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) achieved on Wednesday, however. Just when it looked as if Teva Pharmaceutical shares were going to turn things around and start to claw their way higher again — after getting thumped following a miserable quarterly report — the rug gets pulled out from underneath it. TEVA stock fell 2.7% on Wednesday, moving back within easy reach of new multi-year lows hit last week.
JERUSALEM/LONDON/FRANKFURT, Aug 16 (Reuters) - Teva Pharmaceutical Industries is looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debts and expiring patents. "We are looking for partners ... a series of partners.